NCT04711135 2026-02-12NETTER-PAdvanced Accelerator ApplicationsPhase 2 Active not recruiting11 enrolled 14 charts 2 FDA
NCT02721732 2026-01-29Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are MetastaticM.D. Anderson Cancer CenterPhase 2 Active not recruiting157 enrolled 26 charts